1-aminomethyl-1-(4-methoxyphenyl)cyclohexane | 36970-20-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-aminomethyl-1-(4-methoxyphenyl)cyclohexane
• 英文别名: (1-(4-methoxyphenyl)cyclohexyl)methaneamine；1-Aminomethyl-1-p-anisylcyclohexan；[1-(4-Methoxyphenyl)cyclohexyl]methanamine
• CAS: 36970-20-4
• 化学式: C₁₄H₂₁NO
• mdl: MFCD06213100
• 分子量: 219.327
• InChiKey: RYTWCTSDMHVTPC-UHFFFAOYSA-N

物化性质

• 沸点：
  333.9±25.0 °C(Predicted)
• 密度：
  1.006±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2922199090

反应信息

• 作为反应物：
  描述：

  1-aminomethyl-1-(4-methoxyphenyl)cyclohexane 在 N-甲基吗啉 、 盐酸 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 氢溴酸 、 caesium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 (S)-3-(1H-indol-3-yl)-N-[1-[4-(2-fluoroethoxy)phenyl]cyclohexylmethyl]-2-methyl-2-[3-(4-nitrophenyl)ureido]propionamide
  参考文献：
  名称：

  Structure-activity relationship study towards non-peptidic positron emission tomography (PET) radiotracer for gastrin releasing peptide receptors: Development of [18F] (S)-3-(1H-indol-3-yl)-N-[1-[5-(2-fluoroethoxy)pyridin-2-yl]cyclohexylmethyl]-2-methyl-2-[3-(4-nitrophenyl)ureido]propionamide

  摘要：

  Gastrin-releasing peptide receptors (GRP-Rs, also known as bombesin 2 receptors) are overexpressed in a variety of human cancers, including prostate cancer, and therefore they represent a promising target for in vivo imaging of tumors using positron emission tomography (PET). Structural modifications of the nonpeptidic GRP-R antagonist PD-176252 ((S)-1a) led to the identification of the fluorinated analog (S)-3(1H-indol-3-yl)-N-[1-[5-(2-fluoroethoxy) pyridin-2-yl] cyclohexylmethyl]-2-methyl-2-[3-(4-nitrophenyl) ureido] propionamide ((S)-1m) that showed high affinity and antagonistic properties for GRP-R. This antagonist was stable in rat plasma and towards microsomal oxidative metabolism in vitro. (S)-1m was successfully radiolabeled with fluorine-18 through a conventional radiochemistry procedure. [F-18] (S)-1m showed high affinity and displaceable interaction for GRP-Rs in PC3 cells in vitro. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.10.031
• 作为产物：
  描述：

  1-(4-甲氧基苯基)-1-环己烷甲腈 在 lithium aluminium tetrahydride 、 sodium hydroxide 作用下， 以 乙醚 、 水 为溶剂， 反应 4.33h， 以87%的产率得到1-aminomethyl-1-(4-methoxyphenyl)cyclohexane
  参考文献：
  名称：

  N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT

  摘要：

  本发明涉及一种N2-(2-甲氧基苯基)嘧啶衍生物，其制备方法，以及包含其作为活性成分的用于预防或治疗癌症的药物组合物。本发明的N2-(2-甲氧基苯基)嘧啶衍生物，其光学异构体，或其药学上可接受的盐对抑制间变性淋巴瘤激酶（ALK）活性非常有效，从而可以提高对具有间变性淋巴瘤激酶（ALK）融合蛋白如EML4-ALK和NPM-ALK的癌细胞的治疗效果，因此可以有效地用作预防或治疗癌症的药物组合物。

  公开号：

  US20180111905A1

文献信息

• Heteroaryl Amide Analogues
  申请人：Bakthavatchalam Rajagopal

  公开号：US20120190680A1

  公开（公告）日：2012-07-26

  Compounds, pharmaceutical compositions, and methods of use are disclosed for heteroaryl amide analogues of formula Ia and/or Ib: In certain embodiments, the heteroaryl amide analogues are agonists and/or ligands of dopamine receptors and may be useful, inter alia, for the treatment of a condition responsive to P2X 7 receptor modulation, for example, pain, inflammation, a neurological or neurodegenerative disorder, a cardiovascular disorder, an ocular disorder or an immune system disorder.

  本发明揭示了公式Ia和/或Ib的杂环酰胺类似物的化合物、制药组合物和使用方法：在某些实施例中，杂环酰胺类似物是多巴胺受体的激动剂和/或配体，可用于治疗对P2X7受体调节有反应的疾病，例如疼痛、炎症、神经或神经退行性疾病、心血管疾病、眼部疾病或免疫系统疾病等。
• [EN] N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT<br/>[FR] DÉRIVÉ DE N2-(2-MÉTHOXYPHÉNYL)PYRIMIDINE, PROCÉDÉ POUR LE PRÉPARER ET COMPOSITION PHARMACEUTIQUE POUR LA PRÉVENTION OU LE TRAITEMENT DU CANCER LE CONTENANT EN TANT QU'INGRÉDIENT ACTIF<br/>[KO] N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
  申请人：KOREA RES INST CHEMICAL TECH

  公开号：WO2016167511A2

  公开（公告）日：2016-10-20

  본 발명은 N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물에 관한 것으로, 본 발명에 따른 N2-(2-메톡시페닐)피리미딘 유도체, 이의 광학 이성질체, 또는 이의 약학적으로 허용 가능한 염은 역형성 림프종 키나아제 (ALK)를 억제하는 활성이 우수해, 이에 따른 EML4-ALK, NPM-ALK 등의 역형성 림프종 키나아제 (ALK) 융합 단백질을 가진 암세포에 대한 치료 효과가 우수하므로 암의 예방 또는 치료용 약학적 조성물로 유용하게 사용될 수 있다.
• Structure-activity relationship study towards non-peptidic positron emission tomography (PET) radiotracer for gastrin releasing peptide receptors: Development of [18F] (S)-3-(1H-indol-3-yl)-N-[1-[5-(2-fluoroethoxy)pyridin-2-yl]cyclohexylmethyl]-2-methyl-2-[3-(4-nitrophenyl)ureido]propionamide
  作者：Enza Lacivita、Ermelinda Lucente、Chantal Kwizera、Ines F. Antunes、Mauro Niso、Paola De Giorgio、Roberto Perrone、Nicola A. Colabufo、Philip H. Elsinga、Marcello Leopoldo

  DOI：10.1016/j.bmc.2016.10.031

  日期：2017.1

  Gastrin-releasing peptide receptors (GRP-Rs, also known as bombesin 2 receptors) are overexpressed in a variety of human cancers, including prostate cancer, and therefore they represent a promising target for in vivo imaging of tumors using positron emission tomography (PET). Structural modifications of the nonpeptidic GRP-R antagonist PD-176252 ((S)-1a) led to the identification of the fluorinated analog (S)-3(1H-indol-3-yl)-N-[1-[5-(2-fluoroethoxy) pyridin-2-yl] cyclohexylmethyl]-2-methyl-2-[3-(4-nitrophenyl) ureido] propionamide ((S)-1m) that showed high affinity and antagonistic properties for GRP-R. This antagonist was stable in rat plasma and towards microsomal oxidative metabolism in vitro. (S)-1m was successfully radiolabeled with fluorine-18 through a conventional radiochemistry procedure. [F-18] (S)-1m showed high affinity and displaceable interaction for GRP-Rs in PC3 cells in vitro. (C) 2016 Elsevier Ltd. All rights reserved.
• N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：US20180111905A1

  公开（公告）日：2018-04-26

  The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.

  本发明涉及一种N2-(2-甲氧基苯基)嘧啶衍生物，其制备方法，以及包含其作为活性成分的用于预防或治疗癌症的药物组合物。本发明的N2-(2-甲氧基苯基)嘧啶衍生物，其光学异构体，或其药学上可接受的盐对抑制间变性淋巴瘤激酶（ALK）活性非常有效，从而可以提高对具有间变性淋巴瘤激酶（ALK）融合蛋白如EML4-ALK和NPM-ALK的癌细胞的治疗效果，因此可以有效地用作预防或治疗癌症的药物组合物。